FDA Declines Cingulate's ADHD Drug CTx-1301 Over Manufacturing Concerns
Decision brief
Answer first · skim in under a minute
The U.S. Food and Drug Administration (FDA) has declined to approve Cingulate's attention deficit hyperactivity disorder (ADHD) treatment, CTx-1301, due to manufacturing-related concerns. While the drug's safety and effectiveness were not questioned, the Complete Response Letter (CRL) signifies a delay in the company's market entry.
The FDA declined to approve Cingulate's ADHD candidate CTx-1301 on June 2, 2026, after a Complete Response Letter focused on chemistry, manufacturing, and controls rather than clinical safety or efficacy gaps.
Contents12 sections
Key Takeaways
- CRL focused on Chemistry, Manufacturing, and Controls information requests.
- No clinical safety or efficacy concerns were identified in the company's description of the letter.
- NDA acceptance came in October 2025 with a PDUFA target of May 31, 2026.
- Cingulate reported nearly $30 million cash to support resubmission into 2027.
What did the FDA say about CTx-1301?
Cingulate announced on June 2, 2026, that the FDA issued a Complete Response Letter for its NDA for CTx-1301 (dexmethylphenidate HCl).
Per the company's SEC Exhibit 99.1 press release, the letter identified specific CMC information requests.
Management said the FDA did not currently identify issues related to clinical safety or efficacy.
How does a CMC CRL differ from a clinical rejection?
A manufacturing-focused CRL usually means additional process, stability, or quality documentation—not new pivotal trials.
That distinction matters for valuation because timelines and capital needs differ from efficacy failures.
Reuters likewise reported the decline as manufacturing-related; see Reuters coverage dated June 2, 2026.
What is the clinical and regulatory backdrop for CTx-1301?
CTx-1301 is a once-daily timed-release dexmethylphenidate tablet built on Cingulate's Precision Timed Release platform.
The FDA accepted the NDA in October 2025 and set a PDUFA target action date of May 31, 2026.
ADHD remains a large, crowded stimulant market where delivery profiles and adherence claims drive differentiation.
How is Cingulate funding the resubmission?
CEO Shane J. Schaffer said nearly $30 million in cash reserves should cover CMC remediation, resubmission, and pre-commercial activities into 2027.
The company expects a prompt submission of the requested manufacturing information.
Investors should watch the resubmission clock and any Class 1 versus Class 2 review designation after filing.
- CRL date: June 2, 2026
- Prior PDUFA target: May 31, 2026
- Cash cited: nearly $30 million
What should competitors and payers watch next?
A clean clinical package with a CMC delay still leaves room for a later launch if manufacturing questions close.
Payers will care more about comparative adherence data than about the temporary CRL itself.
Other ADHD programs with novel delivery systems face the same CMC scrutiny that has tripped multiple recent NDAs.
What remains unproven after the CRL?
The public record does not detail which unit operations or specs triggered the CMC requests.
Until resubmission and a new action date, approval timing is unknown.
Commercial uptake assumptions should stay on hold until labeling and supply readiness are clearer.
How common are CMC-only complete response letters?
Recent FDA cycles have produced multiple CRLs that leave efficacy untouched while demanding deeper manufacturing packages.
For a reformulated stimulant like CTx-1301, inspectors often scrutinize timed-release uniformity, impurity controls, and commercial-scale process validation.
Sponsors that already have a manufacturing partner engaged can sometimes answer information requests faster than those that must change sites mid-review.
What commercial stakes ride on a clean resubmission?
ADHD remains a high-volume outpatient market where once-daily profiles compete on onset, duration, and dosing convenience for patients and caregivers.
A CMC delay pushes launch planning, sample supply, and payer dossier work to the right without necessarily destroying the clinical story.
Cingulate's nearly $30 million cash figure is therefore a runway statement as much as a balance-sheet footnote for 2026 and 2027 planning.
Investors should watch for any hint that FDA wants new bioequivalence or stability lots that would stretch the calendar beyond a short review cycle.
Until the resubmission package is public, treat manufacturing remediation timelines as the main binary event for CTx-1301 valuation rather than new efficacy debates.
Related NovaPharma coverage
- FDA clinical trial transparency enforcement guide
- Astellas cost cuts and FDA Moderna vaccine news
- Biopharma news week of June 2026
Frequently Asked Questions
Why did the FDA decline CTx-1301?
On June 2, 2026, Cingulate said the FDA issued a Complete Response Letter seeking specific Chemistry, Manufacturing, and Controls information. The agency did not raise clinical safety or efficacy concerns in that letter.
What is CTx-1301?
CTx-1301 is a once-daily dexmethylphenidate hydrochloride tablet that uses Cingulate's Precision Timed Release platform for ADHD. The active ingredient class has been used in approved ADHD products for years.
What is Cingulate's next step after the CRL?
The company said it is completing CMC work with its manufacturing partner and plans a prompt resubmission. It cited nearly $30 million in cash reserves to fund resubmission and pre-commercial work into 2027.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for CTx-1301.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
